We considered that a regimen of savolitinib + osimertinib combination sometimes may still be potentially beneficial for NSCLC patients with low-GCN-level MET amplification, which may provide some thought-provoking ideas for the treatment options for NSCLC patients with acquired low-level MET amplification and effectively make up for the shortcomings of the HATTON test in patients with low-level MET amplification. This evidence concerns the gene MET and non-small cell lung carcinoma.